EUVIMEDEUVIMED entdecken
Crossref

The Responsible Development of Adeno-Associated Virus Gene Therapies

James M Wilson, Arthur L Caplan

Human Gene Therapy · 2025

DOI: 10.1177/10430342251359668 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2025. Verfasst von James M Wilson und 1 weiteren Autor:innen. Beteiligte Einrichtung: GEMMA Biotherapeutics Inc., Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several unexpected fatalities in patients who received adeno-associated virus (AAV)-based gene therapies have recently occurred. These tragic events have cast a pall over the entire sector with some stakeholders suggesting that AAV is patently unsafe as a gene delivery platform and ought not to be pursued. This conclusion is not warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusGenetic TherapyGenetic VectorsHumansGene Transfer Techniques

Stichwörter der Autor:innen

AAVclinical developmentsafetytranslational medicine

Autor:innen und Institutionen

  • GEMMA Biotherapeutics Inc., Philadelphia, Pennsylvania, USA.
  • NYU Grossman School of Medicine, New York, New York, USA.

Zitieren

APA

Wilson, J. M., & Caplan, A. L. (2025). The Responsible Development of Adeno-Associated Virus Gene Therapies. Human Gene Therapy. https://doi.org/10.1177/10430342251359668

Vancouver

Wilson JM, Caplan AL. The Responsible Development of Adeno-Associated Virus Gene Therapies. Human Gene Therapy. 2025. doi:10.1177/10430342251359668

BibTeX
@article{Wilson2025,
  author = {Wilson, James M and Caplan, Arthur L},
  title = {The Responsible Development of Adeno-Associated Virus Gene Therapies},
  journal = {Human Gene Therapy},
  year = {2025},
  doi = {10.1177/10430342251359668}
}
Kostenlos starten →